Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Robert Holloway, MD

    TitleAssistant Professor of Clinical Psychiatry & The Behavioral Sciences and Pediatrics
    SchoolKeck School of Medicine of USC
    DepartmentPediatrics
    AddressCHLA 4650 W. Sunset Blvd.
    Off Campus
    Los Angeles California 90026

       Bibliographic 
       Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Robinson MT, Vickrey BG, Holloway RG, Chong K, Williams LS, Brook RH, Leng M, Parikh P, Zingmond DS. The lack of documentation of preferences in a cohort of adults who died after ischemic stroke. Neurology. 2016 May 31; 86(22):2056-62..
        View in: PubMed
      2. Creutzfeldt CJ, Robinson MT, Holloway RG. Neurologists as primary palliative care providers: Communication and practice approaches. Neurol Clin Pract. 2016 Feb; 6(1):40-48..
        View in: PubMed
      3. Stroupe KT, Weaver FM, Cao L, Ippolito D, Barton BR, Burnett-Zeigler IE, Holloway RG, Vickrey BG, Simuni T, Follett KA. Cost of deep brain stimulation for the treatment of Parkinson's disease by surgical stimulation sites. Mov Disord. 2014 Nov; 29(13):1666-74..
        View in: PubMed
      4. Xian Y, Holloway RG, Smith EE, Schwamm LH, Reeves MJ, Bhatt DL, Schulte PJ, Cox M, Olson DM, Hernandez AF, Lytle BL, Anstrom KJ, Fonarow GC, Peterson ED. Racial/Ethnic differences in process of care and outcomes among patients hospitalized with intracerebral hemorrhage. Stroke. 2014 Nov; 45(11):3243-50..
        View in: PubMed
      5. Dodel R, Jönsson B, Reese JP, Winter Y, Martinez-Martin P, Holloway R, Sampaio C, Ružicka E, Hawthorne G, Oertel W, Poewe W, Stebbins G, Rascol O, Goetz CG, Schrag A. Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease. Mov Disord. 2014 Feb; 29(2):169-76..
        View in: PubMed
      6. Weaver FM, Stroupe KT, Cao L, Holloway RG, Vickrey BG, Simuni T, Hendricks A, Ippolito D. Parkinson's disease medication use and costs following deep brain stimulation. Mov Disord. 2012 Sep 15; 27(11):1398-403..
        View in: PubMed
      7. Kim SY, De Vries R, Holloway RG, Wilson R, Parnami S, Kim HM, Frank S, Kieburtz K. Sham surgery controls in Parkinson's disease clinical trials: views of participants. Mov Disord. 2012 Sep 15; 27(11):1461-5..
        View in: PubMed
      8. Kim SY, Wilson RM, Kim HM, Holloway RG, De Vries RG, Frank SA, Kieburtz K. Comparison of enrollees and decliners of Parkinson disease sham surgery trials. Mov Disord. 2012 Apr; 27(4):506-11..
        View in: PubMed
      9. Pogoda TK, Cramer IE, Meterko M, Lin H, Hendricks A, Holloway RG, Charns MP. Patient and organizational factors related to education and support use by Veterans with Parkinson's disease. Mov Disord. 2009 Oct 15; 24(13):1916-24..
        View in: PubMed
      10. Yurcheshen ME, Guttuso T, McDermott M, Holloway RG, Perlis M. Effects of gabapentin on sleep in menopausal women with hot flashes as measured by a Pittsburgh Sleep Quality Index factor scoring model. J Womens Health (Larchmt). 2009 Sep; 18(9):1355-60..
        View in: PubMed
      11. Dorsey ER, Thompson JP, Frasier M, Sherer T, Fiske B, Nicholson S, Johnston SC, Holloway RG, Moses H. Funding of Parkinson research from industry and US federal and foundation sources. Mov Disord. 2009 Apr 15; 24(5):731-7..
        View in: PubMed
      12. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15; 23(15):2129-70..
        View in: PubMed
      13. Frank SA, Wilson R, Holloway RG, Zimmerman C, Peterson DR, Kieburtz K, Kim SY. Ethics of sham surgery: perspective of patients. Mov Disord. 2008 Jan; 23(1):63-8..
        View in: PubMed
      14. Biglan KM, Holloway RG, McDermott MP, Richard IH. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology. 2007 Jul 10; 69(2):187-95..
        View in: PubMed
      15. Noyes K, Liu H, Holloway R, Dick AW. Accuracy of Medicare claims data in identifying Parkinsonism cases: comparison with the Medicare current beneficiary survey. Mov Disord. 2007 Mar 15; 22(4):509-14..
        View in: PubMed
      16. Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, Stern MB, Tilley BC, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, Van Hilten JJ, LaPelle N. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 2007 Jan; 22(1):41-7..
        View in: PubMed
      17. Noyes K, Liu H, Li Y, Holloway R, Dick AW. Economic burden associated with Parkinson's disease on elderly Medicare beneficiaries. Mov Disord. 2006 Mar; 21(3):362-72..
        View in: PubMed
      18. Noyes K, Dick AW, Holloway RG. Pramipexole versus levodopa in patients with early Parkinson's disease: effect on generic and disease-specific quality of life. Value Health. 2006 Jan-Feb; 9(1):28-38..
        View in: PubMed
      19. Noyes K, Dick AW, Holloway RG. Pramipexole v. levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trial. Med Decis Making. 2004 Sep-Oct; 24(5):472-85..
        View in: PubMed
      20. Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, Giladi N, Holloway RG, Moore CG, Wenning GK, Yahr MD, Seidl L. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004 Sep; 19(9):1020-8..
        View in: PubMed
      21. Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O'Connell C, Ross T, Richard K, Watts A. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004 Jul; 61(7):1044-53..
        View in: PubMed
      22. Welsh M, McDermott MP, Holloway RG, Plumb S, Pfeiffer R, Hubble J. Development and testing of the Parkinson's disease quality of life scale. Mov Disord. 2003 Jun; 18(6):637-45..
        View in: PubMed
      Robert's Networks
      Related Concepts
      Derived automatically from this person's publications.
      _
      Related Authors at USC
      People who share related concepts with this person.
      _
      Same Department
      Back to TOP